Compare REX AI Equity Premium Income ETF (AIPI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Pfizer Inc — how do they compare? REX AI Equity Premium Income ETF trades at $37.25, while Pfizer Inc trades at $26.54 (market cap $151.73B). The key difference: Pfizer Inc pays a 6.46% dividend while REX AI Equity Premium Income ETF pays none, and Pfizer Inc is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | PFE | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $28.56 |
52-Week Low | $32.45 | $23.60 |
Market Cap | — | $151.73B |
Volume | — | 29,869,932 |
Enterprise Value | — | $203.22B |
Dividend Yield | — | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.34, up 1.52% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock pays high weekly dividends, recently transitioning to this frequency to attract income investors. Key resistance lies at $38, with support at $36.
Outlook is mixed: high dividend yields near 35% offer income appeal, but sustainability concerns and structural risks from option-writing strategies pose challenges. Investors should weigh income benefits against potential NAV erosion if AI market momentum slows.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
